| Valuation |
4.0 |
auto |
P/E -10.0 (loss) |
| Liquidity |
10.0 |
auto |
Current ratio 3.29 |
| Growth |
1.0 |
auto |
Revenue growth -29.8% |
| Profitability |
1.5 |
auto |
Net margin -145.2% |
| Efficiency |
1.6 |
auto |
ROE -28.9% |
| Leadership Tenure |
9.0 |
ai |
Stéphane Bancel has been CEO since 2011, co-founded the company's commercial trajectory, and remains the public face with strong continuity through the COVID boom and post-pandemic transition. |
| Ownership Alignment |
9.3 |
auto |
Insider holding 7.32% |
| Strategic Vision |
8.5 |
ai |
Clear mRNA platform roadmap spanning respiratory vaccines (COVID, flu, RSV, combo), oncology (mRNA-4157/individualized neoantigen with Merck), rare disease, and latent viruses (CMV) — ambitious 10+ year pipeline articulated by Bancel. |
| Focus / Clarity |
8.6 |
ai |
Pure-play mRNA platform company; all programs leverage the same LNP/mRNA technology stack across vaccines and therapeutics — exceptionally focused single-platform thesis. |
| Diversification |
5.2 |
ai |
Revenue still ~90% concentrated in Spikevax COVID vaccine (~$3B FY2024), with pipeline diversification still pre-commercial; mRESVIA launched but immaterial — concentrated by stage, not strategy. |
| Maturity / Revenue |
5.5 |
ai |
Revenue $1.9B |
| Growth Potential |
9.0 |
ai |
Massive forward TAM across mRNA oncology (Merck INT Phase 3 melanoma, multiple tumor types), CMV vaccine ($2-5B opportunity), combo respiratory, and rare disease — low penetration with platform optionality is the textbook v2 rerating setup. |
| Volatility |
6.4 |
auto |
β 1.34 · D/E 15.09 |
| Market Standing |
7.7 |
auto |
Market cap $18.7B |
| Competitive Moat |
8.4 |
ai |
Top-2 mRNA platform globally with deep IP portfolio, manufacturing scale built during COVID, and R&D >100% of revenue; contested by Pfizer/BioNTech but holds genuine technological moat in LNP delivery and mRNA design. |